Similar trends were observed for changes in total cholesterol .
Implication sGiven the available data , the addition of ezetimibe to ongoing simvastatin , atorvastatin , or rosuvastatin monotherapy offers greater reduction in LDL-C among patients at high risk of CVD compared to doubling the initial statin dose
Purpose While statins are used as first-line treatments for high-risk patients with hypercholesterolemia , statin monotherapy is often insufficient to achieve target low-density lipoprotein cholesterol ( LDL-C ) levels .
Second-line treatment options include up-titration of statin dose , switching to a more potent statin , or combination therapy , e.g. , with ezetimibe .
The aim of this study was to evaluate the efficacy of adding ezetimibe to simvastatin , atorvastatin , or rosuvastatin monotherapy versus doubling the dosage or switching to a higher-potency statin in a population of patients with hypocholesterolemia at high risk of cardiovascular disease ( CVD ) and who had been previously treated with a statin .
Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease.
This r and omised , double-blind , placebo (PBO)-controlled study evaluated the efficacy and safety of ezetimibe ( EZE ) co-administered with ongoing atorvastatin ( ATV ) therapy in 450 hypercholesterolemic patients with coronary heart disease ( CHD ) who had not achieved their low-density lipoprotein cholesterol ( LDL-C ) goal < or = 2.60 mmol/l while on a stable dose of ATV 10 or 20 mg/day for > or = 6 weeks . After a 4-week diet/baseline active run-in period , patients with LDL-C > 2.60 mmol/l and < or = 4.20 mmol/l were stratified by ATV dose and r and omised ( 1 : 1 ) to EZE 10 mg or PBO for 6 weeks while continuing open-label ATV . Significantly more patients achieved an LDL-C goal < or = 2.6 mmol/l with EZE than PBO ( 81.3 vs. 21.8 % ; p < or = 0.001 ) . Compared to PBO , co-administration of EZE with ongoing ATV led to significantly ( p < or = 0.001 ) greater reductions in LDL-C , total cholesterol , triglycerides , non-high-density lipoprotein cholesterol ( non-HDL-C ) , and apolipoprotein B ; HDL-C was significantly ( p < or = 0.05 ) increased . Co-administration of EZE and ATV was well tolerated , with an overall safety profile similar to ATV alone
Similar trends were observed for changes in total cholesterol .
Implication sGiven the available data , the addition of ezetimibe to ongoing simvastatin , atorvastatin , or rosuvastatin monotherapy offers greater reduction in LDL-C among patients at high risk of CVD compared to doubling the initial statin dose
Purpose While statins are used as first-line treatments for high-risk patients with hypercholesterolemia , statin monotherapy is often insufficient to achieve target low-density lipoprotein cholesterol ( LDL-C ) levels .
Second-line treatment options include up-titration of statin dose , switching to a more potent statin , or combination therapy , e.g. , with ezetimibe .
The aim of this study was to evaluate the efficacy of adding ezetimibe to simvastatin , atorvastatin , or rosuvastatin monotherapy versus doubling the dosage or switching to a higher-potency statin in a population of patients with hypocholesterolemia at high risk of cardiovascular disease ( CVD ) and who had been previously treated with a statin .